Baseline demographics and clinical characteristics
| . | Zanubrutinib (n = 324) . | Ibrutinib (n = 324) . |
|---|---|---|
| Age, median (range), y | 67.0 (35-90) | 67.5 (35-89) |
| <65, n (%) | 126 (38.9) | 125 (38.6) |
| ≥65 to <75, n (%) | 124 (38.3) | 130 (40.1) |
| ≥75, n (%) | 74 (22.8) | 69 (21.3) |
| Sex, n (%) | ||
| Men | 212 (65.4) | 231 (71.3) |
| Women | 112 (34.6) | 93 (28.7) |
| Race, n (%) | ||
| White | 261 (80.6) | 264 (81.5) |
| Asian | 45 (13.9) | 44 (13.6) |
| Black or African American | 4 (1.2) | 2 (0.6) |
| Not reported | 8 (2.5) | 12 (3.7) |
| Other | 6 (1.9) | 2 (0.6) |
| BMI, mean (SD), kg/m2 | 27.2 (4.9) | 27.1 (4.6) |
| <18.5, n (%) | 4 (1.2) | 2 (0.6) |
| ≥18.5 to <25, n (%) | 111 (34.3) | 112 (34.6) |
| ≥25 to <30 kg/m2, n (%) | 115 (35.5) | 131 (40.4) |
| ≥30 kg/m2, n (%) | 89 (27.5) | 74 (22.8) |
| Missing | 5 (1.5) | 5 (1.5) |
| Key hematologic parameters, n (%) | ||
| Hemoglobin-low | ||
| G1-G2 | 145 (44.8) | 160 (49.4) |
| G3-G4 | 9 (2.8) | 9 (2.8) |
| Neutrophil count-low | ||
| G1-G2 | 38 (11.7) | 45 (13.9) |
| G3-G4 | 13 (4.0) | 16 (4.9) |
| Platelet count-low | ||
| G1-G2 | 181 (55.9) | 178 (54.9) |
| G3-G4 | 9 (2.8) | 14 (4.3) |
| eGFR, mean (SD), mL/min/1.73 m2 | 72.8 (17.8) | 70.2 (17.8) |
| <30, n (%) | 1 (0.3) | 4 (1.2) |
| ≥30 to <60, n (%) | 85 (26.2) | 95 (29.3) |
| ≥60, n (%) | 238 (73.5) | 225 (69.4) |
| Type 2 diabetes, n (%) | 67 (20.7) | 63 (19.4) |
| Hyperlipidemia, n (%) | 95 (29.3) | 80 (24.7) |
| Heart rate, mean (SD), beats per min | 76.9 (10.7) | 76.2 (11.7) |
| Hypertension diagnosis at baseline, n (%)∗ | 165 (50.9) | 162 (50.0) |
| Systolic blood pressure at baseline, mean (SD), mm Hg | 128.9 (16.0) | 127.3 (15.1) |
| <120, n (%) | 96 (29.6) | 99 (30.6) |
| 120-129, n (%) | 78 (24.1) | 78 (24.1) |
| 130-139, n (%) | 64 (19.8) | 72 (22.2) |
| ≥140, n (%) | 86 (26.5) | 75 (23.1) |
| Antihypertensive drug use at baseline, n (%) | ||
| No | 169 (52.2) | 178 (54.9) |
| Yes | 155 (47.8) | 146 (45.1) |
| . | Zanubrutinib (n = 324) . | Ibrutinib (n = 324) . |
|---|---|---|
| Age, median (range), y | 67.0 (35-90) | 67.5 (35-89) |
| <65, n (%) | 126 (38.9) | 125 (38.6) |
| ≥65 to <75, n (%) | 124 (38.3) | 130 (40.1) |
| ≥75, n (%) | 74 (22.8) | 69 (21.3) |
| Sex, n (%) | ||
| Men | 212 (65.4) | 231 (71.3) |
| Women | 112 (34.6) | 93 (28.7) |
| Race, n (%) | ||
| White | 261 (80.6) | 264 (81.5) |
| Asian | 45 (13.9) | 44 (13.6) |
| Black or African American | 4 (1.2) | 2 (0.6) |
| Not reported | 8 (2.5) | 12 (3.7) |
| Other | 6 (1.9) | 2 (0.6) |
| BMI, mean (SD), kg/m2 | 27.2 (4.9) | 27.1 (4.6) |
| <18.5, n (%) | 4 (1.2) | 2 (0.6) |
| ≥18.5 to <25, n (%) | 111 (34.3) | 112 (34.6) |
| ≥25 to <30 kg/m2, n (%) | 115 (35.5) | 131 (40.4) |
| ≥30 kg/m2, n (%) | 89 (27.5) | 74 (22.8) |
| Missing | 5 (1.5) | 5 (1.5) |
| Key hematologic parameters, n (%) | ||
| Hemoglobin-low | ||
| G1-G2 | 145 (44.8) | 160 (49.4) |
| G3-G4 | 9 (2.8) | 9 (2.8) |
| Neutrophil count-low | ||
| G1-G2 | 38 (11.7) | 45 (13.9) |
| G3-G4 | 13 (4.0) | 16 (4.9) |
| Platelet count-low | ||
| G1-G2 | 181 (55.9) | 178 (54.9) |
| G3-G4 | 9 (2.8) | 14 (4.3) |
| eGFR, mean (SD), mL/min/1.73 m2 | 72.8 (17.8) | 70.2 (17.8) |
| <30, n (%) | 1 (0.3) | 4 (1.2) |
| ≥30 to <60, n (%) | 85 (26.2) | 95 (29.3) |
| ≥60, n (%) | 238 (73.5) | 225 (69.4) |
| Type 2 diabetes, n (%) | 67 (20.7) | 63 (19.4) |
| Hyperlipidemia, n (%) | 95 (29.3) | 80 (24.7) |
| Heart rate, mean (SD), beats per min | 76.9 (10.7) | 76.2 (11.7) |
| Hypertension diagnosis at baseline, n (%)∗ | 165 (50.9) | 162 (50.0) |
| Systolic blood pressure at baseline, mean (SD), mm Hg | 128.9 (16.0) | 127.3 (15.1) |
| <120, n (%) | 96 (29.6) | 99 (30.6) |
| 120-129, n (%) | 78 (24.1) | 78 (24.1) |
| 130-139, n (%) | 64 (19.8) | 72 (22.2) |
| ≥140, n (%) | 86 (26.5) | 75 (23.1) |
| Antihypertensive drug use at baseline, n (%) | ||
| No | 169 (52.2) | 178 (54.9) |
| Yes | 155 (47.8) | 146 (45.1) |
BMI, body mass index; eGFR, estimated glomerular filtration rate; G, grade; SD, standard deviation.
Based on narrow Standardized Medical Dictionary for Regulatory Activities Query and was determined via medical history.